Literature DB >> 17195092

CD95 tyrosine phosphorylation is required for CD95 oligomerization.

Andrea Eberle1, Roland Reinehr, Stephan Becker, Verena Keitel, Dieter Häussinger.   

Abstract

Proapoptotic stimuli, such as CD95 ligand and hydrophobic bile acids induce an epidermal growth factor receptor (EGFR)-catalyzed tyrosine phosphorylation of CD95-death receptor in hepatocytes, as a prerequisite for CD95-translocation to the plasma membrane, formation of the death-inducing signalling complex and execution of apoptotic cell death. However, the molecular role played by CD95 tyrosine phosphorylation remained unclear. The present study shows that CD95-tyrosine phosphorylation is required for CD95-oligomerization. Fluorescence resonance energy transfer (FRET)-analysis in Huh7 hepatoma cells, which were cotransfected with CD95-YFP/CD95-CFP revealed that stimulation of these cells with CD95 ligand, proapoptotic bile acids or hyperosmolarity resulted within 30 min in an intracellular FRET-signal, suggestive for CD95/CD95-oligomerization. After 120 min the FRET-signal was detected in the plasma membrane, indicating translocation of the CD95/CD95-oligomer to the plasma membrane. CD95/CD95-oligomerization was abolished in presence of AG1478 or a JNK-inhibitory peptide, i.e. maneuvers known to prevent EGFR-catalyzed CD95-tyrosine phosphorylation. Transfection studies with YFP/CFP-coupled CD95-mutants, which contain tyrosine/phenylalanine-exchanges in positions 232 and 291 (CD95(Y232,291F)), revealed that at least one tyrosine (Y(232,291))-phosphorylated CD95 is required for CD95/CD95-oligomerization. FRET-studies in mouse embryonic fibroblasts, which in contrast to Huh7 express endogenous CD95, revealed that EGF, but not CD95L induced EGFR-homomerization, whereas CD95 ligand, but not EGF resulted in EGFR/CD95-heteromerization. These findings suggest that EGFR-catalyzed CD95-tyrosine phosphorylation is involved in the CD95/CD95-oligomerization process, which is induced by proapoptotic stimuli and is required for apoptosis induction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195092     DOI: 10.1007/s10495-006-0003-2

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  6 in total

1.  Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.

Authors:  Alison Bamberg; Elizabeth F Redente; Steve D Groshong; Rubin M Tuder; Carlyne D Cool; Rebecca C Keith; Benjamin L Edelman; Bart P Black; Gregory P Cosgrove; Murry W Wynes; Douglas Curran-Everett; Stijn De Langhe; Luis A Ortiz; Andrew Thorburn; David W H Riches
Journal:  Am J Respir Crit Care Med       Date:  2018-10-01       Impact factor: 21.405

2.  Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.

Authors:  Hossein A Hamed; Yukihiro Yamaguchi; Paul B Fisher; Steven Grant; Paul Dent
Journal:  J Cell Physiol       Date:  2013-10       Impact factor: 6.384

3.  PDE5 inhibitors enhance celecoxib killing in multiple tumor types.

Authors:  Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Seyedmehrad Tavallai; Timothy Webb; Peter Samuel; Adam Conley; Brittany Binion; Harold F Young; Andrew Poklepovic; Sarah Spiegel; Paul Dent
Journal:  J Cell Physiol       Date:  2015-05       Impact factor: 6.384

4.  Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95.

Authors:  Anindita Das; David Durrant; Clint Mitchell; Paul Dent; Surinder K Batra; Rakesh C Kukreja
Journal:  Oncotarget       Date:  2016-01-26

5.  CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner.

Authors:  Clara Quijano-Rubio; Manuela Silginer; Michael Weller
Journal:  Cell Death Discov       Date:  2022-07-29

6.  Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.

Authors:  A Rodríguez-Hernández; E Navarro-Villarán; R González; S Pereira; L B Soriano-De Castro; A Sarrias-Giménez; L Barrera-Pulido; J M Álamo-Martínez; A Serrablo-Requejo; G Blanco-Fernández; A Nogales-Muñoz; A Gila-Bohórquez; D Pacheco; M A Torres-Nieto; J Serrano-Díaz-Canedo; G Suárez-Artacho; C Bernal-Bellido; L M Marín-Gómez; J A Barcena; M A Gómez-Bravo; C A Padilla; F J Padillo; J Muntané
Journal:  Redox Biol       Date:  2015-07-22       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.